Schizophrenia Research
Volume 58, Issue 1 , Pages 43-53 , 1 November 2002

Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia

  • Clara Nowakowski

      Affiliations

    • Department of Psychiatry, University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
    • ,
  • Walter A Kaufmann

      Affiliations

    • Department of Biochemical Pharmacology, University of Innsbruck, Austria
    • ,
  • Christine Adlassnig

      Affiliations

    • Department of Psychiatry, University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
    • ,
  • Hans Maier

      Affiliations

    • Department of Pathology, University of Innsbruck, Austria
    • ,
  • Kayvon Salimi

      Affiliations

    • Department of Psychiatry, University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
    • ,
  • Kurt A Jellinger

      Affiliations

    • Ludwig-Boltzmann-Institute of Clinical Neurobiology, Vienna, Austria
    • ,
  • Josef Marksteiner

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +43-512-504-3712; fax: +43-512-504-3713
    • Department of Psychiatry, University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria

Received 2 September 2001 ,Accepted 10 November 2001.

References 

  1. Arnold SE, Trojanowski JQ. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol. (Berlin). 1996;92:217–231
  2. Bauer R, Mayr A, Lederer W, Needham PL, Kilpatrick IC, Fleischhacker WW, et al. Further evidence that behavioural tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2000;23:46–55
  3. Benjannet S, Leduc R, Adrouche N, Falgueyret JP, Marcinkiewicz M, Seidah NG, et al. Chromogranin B (secretogranin I), a putative precursor of two novel pituitary peptides through processing at paired basic residues. FEBS Lett. 1987;224:142–148
  4. Browning MD, Dudek EM, Rapier JL, Leonard S, Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol. Psychiatry. 1993;34:529–535
  5. Davidsson P, Gottfries J, Bogdanovic N, Ekman R, Karlsson I, Gottfries CG, et al. The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains. Schizophr. Res. 1999;40:23–29
  6. Eastwood SL, Burnet PW, McDonald B, Clinton J, Harrison PJ. Synaptophysin gene expression in human brain: a quantitative in situ hybridization and immunocytochemical study. Neuroscience. 1994;59:881–892
  7. Eastwood SL, Burnet PW, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 1995;66:309–319
  8. Eastwood SL, Cairns NJ, Harrison PJ. Synaptophysin gene expression in schizophrenia: investigation of synaptic pathology in the cerebral cortex. Br. J. Psychiatry. 2000;176:236–242
  9. Forss-Petter S, Danielson P, Battenberg E, Bloom F, Sutcliffe JG. Nucleotide sequence and cellular distribution of rat chromogranin B (secretogranin I) mRNA. J. Mol. Neurosci. 1989;1:63–75
  10. Glombik MM, Kromer A, Salm T, Huttner WB, Gerdes HH. The disulfide-bonded loop of chromogranin B mediates membrane binding and directs sorting from the trans-Golgi network to secretory granules. EMBO J. 1999;18:1059–1070
  11. Harrison PJ. The neuropathological effects of antipsychotic drugs. Schizophr. Res. 1999;40:87–99
  12. Hsu SM, Raine L, Fanger H. Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1981;29:577–580
  13. Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. TIBS. 1991;16:27–30
  14. Jahn R, Schiebler W, Ouimet C, Greengard P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 1985;82:4137–4141
  15. Kaufmann WA, Barnas U, Humpel C, Nowakowski K, DeCol C, Gurka P, et al. Synaptic loss reflected by secretoneurin-like immunoreactivity in the human hippocampus in Alzheimer's disease. Eur. J. Neurosci. 1998;10:1084–1094
  16. Kitao Y, Inada T, Arinami T, Hirotsu C, Aoki S, Iijima Y, et al. A contribution to genome-wide association studies: search for susceptibility loci for schizophrenia using DNA microsatellite markers on chromosomes 19, 20, 21 and 22. Psychiatr. Genet. 2000;10:139–143
  17. Krieckhaus EE, Donahoe JW, Morgan MA. Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol. Psychiatry. 1992;31:560–570
  18. Kroesen S, Marksteiner J, Leitner B, Hogue Angeletti R, Fischer Colbrie R, Winkler H. Rat brain: distribution of immunoreactivity of PE-11, a peptide derived from chromogranin B. Eur. J. Neurosci. 1996;8:2679–2689
  19. Kromer A, Glombik MM, Huttner WB, Gerdes HH. Essential role of the disulfide-bonded loop of chromogranin B for sorting to secretory granules is revealed by expression of a deletion mutant in the absence of endogenous granin synthesis. J. Cell Biol. 1998;140:1331–1346
  20. Landen M, Grenfeldt B, Davidsson P, Stridsberg M, Regland B, Gottfries CG, et al. Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Eur. Neuropsychopharmacol. 1999;9:311–315
  21. Landen M, Davidsson P, Gottfries CG, Grenfeldt B, Stridsberg M, Blennow K. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia. Biol. Psychiatry. 1999;46:1698–1702
  22. Marksteiner J, Bauer R, Kaufmann WA, Weiss E, Barnas U, Maier H. PE-11, a peptide derived from chromogranin B, in the human brain. Neuroscience. 1999;91:1155–1170
  23. Marksteiner J, Lechner T, Kaufmann WA, Gurka P, Humpel C, Nowakowski C, et al. Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease. Acta Neuropathol. (Berlin). 2000;100:205–212
  24. Melloni RH, Hemmendinger LM, Hamos JE, DeGennaro LJ. Synapsin I gene expression in the adult rat brain with comparative analysis of mRNA and protein in the hippocampus. J. Comp. Neurol. 1993;327:507–520
  25. Miller C, Kirchmair R, Troger J, Saria A, Fleischhacker WW, Fischer-Colbrie R, et al. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol. Psychiatry. 1996;39:911–918
  26. Mirnics K, Middleton A, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53–67
  27. Nestler EJ, Greengard P. Synapsin I: a review of its distribution and biological regulation. Prog. Brain Res. 1986;69:323–339
  28. Rosa P, Weiss U, Pepperkok R, Ansorge W, Niehrs C, Stelzer EH, et al. An antibody against secretogranin I (chromogranin B) is packaged into secretory granules. J. Cell Biol. 1989;109:17–34
  29. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry. 1999;45:17–25
  30. van Kammen DP, Peters J, Yao J, Neylan T, Beuger M, Pontius E, et al. CSF chromogranin A-like immunoreactivity in schizophrenia: assessment of clinical and biochemical relationships. Schizophr. Res. 1991;6:31–39
  31. Webster MJ, Shannon WC, Herman MM, Hyde TM, Kleinman JE. Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia. Schizophr. Res. 2001;49:89–98
  32. Weinberger DR. Cell biology of the hippocampal formation in schizophrenia. Biol. Psychiatry. 1999;45:395–402
  33. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 1992;49:497–528
  34. Wouterlood FG. Anterograde neuroanatomical tracing with Phaseolus vulgaris-leucoagglutinin combined with immunocytochemistry of gamma-amino butyric acid, choline acetyltransferase or serotonin. Histochemistry. 1988;89:421–428
  35. Yoo SH. pH- and Ca(2+)-dependent aggregation property of secretory vesicle matrix proteins and the potential role of chromogranins A and B in secretory vesicle biogenesis. J. Biol. Chem. 1996;271:1558–1565

PII: S0920-9964(01)00389-9

Schizophrenia Research
Volume 58, Issue 1 , Pages 43-53 , 1 November 2002

Article Tools

* Image Usage & Resolution